Option chain shows key data for 's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for .

 (CPHRF) Stock, Option Chain

Cipher Pharmaceuticals Inc is a specialty pharmaceutical company. Its products include Dermatology Products, Hospital Acute Care Products, specialty medicines, and Out-Licensed Products among others. The company's geographical operational areas include Canada and the United States.

Cannabis

After-Hours Center

Markets

Movers

Trading Ideas

LVCNF

SEED

ICNAF

SNDL

CPHRF

NINE

CNPOF

ARNA

AUSAF

NXGWF

ALEAF

CNTMF

CWBHF

CURR

CNVCF

CVSI

TLRY

CRBP

XXII

UGRO

YCBD

TBPMF

BMMJ

GNLN

CXXIF

TGODF

GRWG

CRLBF

GTBIF

CANN

CNBX

GAINERS:


	Leviathan Natural Prods (OTC:LVCNF) shares closed up 14.86% at $0.52 with an estimated market cap of $43.9M.


Marijuana Stock Movers For October 8, 2021

News

NDVAF

RHNMF

HEXO

TCNNF

TRSSF

MBII

ZYNE

CBWTF

GENE

BLOZF

GAINERS:


	Tetra Bio Pharma (OTC:TBPMF) shares closed up 21.96% at $0.22 with an estimated market cap of $88.1M.


Top Cannabis Movers For October 5, 2021

WRLD

INLB

NWVCF

EPWCF

HRVSF

MMNFF

GAINERS:


	Mexco Energy (AMEX:MXC) shares closed up 12.88% at $11.74 with an estimated market cap of $24.6M.


Aurora &amp; Trulieve Among Top Cannabis Movers For Oct 1, 2021 - Full Canna Movers Index

CIPHER PHARMS INC ORD by Cipher Pharmaceuticals, Inc.

Cipher Pharmaceuticals Inc

Guidance

Micron Sees Q2 Revenue $7.7B-$8.1B vs $9.00B Est; Adj. EPS $1.33-$1.53 vs $1.92 Est

Contracts

PLTR

Palantir Extends Long-standing Partnership With US Army To Deliver Army Vantage Capability In Support Of Army Data Platform; Total Value Of Agreement Is $400.74M For Period Of Up To Four Years, With Total Available Ceiling Of $618.87M

<ul>
<li><i>Breakthrough provides the first-ever certificates of authenticity and compliance for independent verification of AI training, inference, and benchmarks at runtime.</i></li>
<li><i>The solution delivers on-silicon, real-time governance — an industry-first created from two years of intensive research joined by advisors at Stanford and MIT.</i></li>
<li><i>Delivered this month to first clients with transformative applications across the life sciences, public sector, finance, and media to certify smarter, safer AI systems and agents.</i></li>
</ul>
<p><a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.eqtylab.io%2F&amp;esheet=54168229&amp;newsitemid=20241218897420&amp;lan=en-US&amp;anchor=EQTY+Lab&amp;index=1&amp;md5=c10a00935d9dd60e9565ee82b154c342">EQTY Lab</a>, in collaboration with <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.intel.com%2Fcontent%2Fwww%2Fus%2Fen%2Fhomepage.html&amp;esheet=54168229&amp;newsitemid=20241218897420&amp;lan=en-US&amp;anchor=Intel&amp;index=2&amp;md5=f77b88357a53a6279a5450ba2839b0c5">Intel</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/INTC#NASDAQ">INTC</a>) and <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.nvidia.com%2Fen-us%2F&amp;esheet=54168229&amp;newsitemid=20241218897420&amp;lan=en-US&amp;anchor=NVIDIA&amp;index=3&amp;md5=ea11821b4ed59a27d1588b10ea5483af">NVIDIA</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), announced today the release of the Verifiable Compute AI framework, the first hardware-based solution to govern and audit AI workflows. Verifiable Compute represents a significant leap forward in ensuring that AI is explainable, accountable, and secure at runtime. It gives consumers and businesses new confidence to accelerate AI adoption and development.</p>


INTC

NVDA

EQTY Lab, In Collaboration With Intel And NVIDIA Announces The Release Of The Verifiable Compute AI Framework, The First Hardware-Based Solution To Govern And Audit AI Workflows

Earnings

Micron Technology Q1 2025 Adj. EPS $1.79 Beats $1.76 Estimate, Sales $8.709 Miss $8.721B Estimate

<p>Throughout the last three months, 8 analysts have evaluated Noble Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NE#NYSE">NE</a>), offering a diverse set of opinions from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $45.38, with a high estimate of $64.00 and a low estimate of $37.00. Highlighting a 10.51% decrease, the current average has fallen from the previous average price target of $50.71. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734555665_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The standing of Noble Corp among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$42.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Arun Jayaram</td>
<td>JP Morgan</td>
<td>Announces</td>
<td>Neutral</td>
<td>$37.00</td>
<td>-</td>
</tr>
<tr>
<td>Nikhil Gupta</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$40.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$38.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>James West</td>
<td>Evercore ISI Group</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$64.00</td>
<td>$67.00</td>
</tr>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$48.00</td>
<td>$54.00</td>
</tr>
<tr>
<td>Charles Minervino</td>
<td>Susquehanna</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$40.00</td>
<td>$47.00</td>
</tr>
<tr>
<td>Eddie Kim</td>
<td>Barclays</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$54.00</td>
<td>$55.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Noble Corp. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Noble Corp compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Noble Corp's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>To gain a panoramic view of Noble Corp's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/NE/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Noble Corp analyst ratings.</strong></a></p>
<h2>Get to Know Noble Corp Better</h2>
<p>Noble Corp PLC is an offshore drilling contractor for the oil and gas industry that provides contract drilling services to the international oil and gas industry with its fleet of mobile offshore drilling units. The company focuses on a high-specification fleet of floating and jackup rigs and the deployment of its drilling rigs in oil and gas basins around the world.</p>
<h3>Noble Corp: Financial Performance Dissected</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> Noble Corp displayed positive results in 3 months. As of 30 September, 2024, the company achieved a solid revenue growth rate of approximately <strong>14.78%</strong>. This indicates a notable increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Energy sector.</p>
<p><strong>Net Margin:</strong> Noble Corp's net margin excels beyond industry benchmarks, reaching <strong>7.65%</strong>. This signifies efficient cost management and strong financial health.</p>
<p><strong>Return on Equity (ROE):</strong> Noble Corp's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>1.41%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Noble Corp's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>0.9%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Noble Corp's debt-to-equity ratio is below the industry average. With a ratio of <b>0.42</b>, the company relies less on debt financing, maintaining a healthier balance between debt and equity, which can be viewed positively by investors.</p>
<h2>How Are Analyst Ratings Determined?</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Analyst Ratings

Beyond The Numbers: 8 Analysts Discuss Noble Corp Stock

<p>Brighthouse Finl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BHF#NASDAQ">BHF</a>) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<p>The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets, analyzed by analysts, offer insights with an average target of $48.0, a high estimate of $52.00, and a low estimate of $41.00. This upward trend is evident, with the current average reflecting a 2.67% increase from the previous average price target of $46.75.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734555657_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Brighthouse Finl. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$52.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Alex Scott</td>
<td>Barclays</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$52.00</td>
<td>$48.00</td>
</tr>
<tr>
<td>Elyse Greenspan</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Underweight</td>
<td>$41.00</td>
<td>$40.00</td>
</tr>
<tr>
<td>John Barnidge</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Neutral</td>
<td>$47.00</td>
<td>$44.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Brighthouse Finl. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Brighthouse Finl compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts navigate through adjustments in price targets, providing estimates for Brighthouse Finl's future value. Comparing current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>Navigating through these analyst evaluations alongside other financial indicators can contribute to a holistic understanding of Brighthouse Finl's market standing. Stay informed and make data-driven decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/BHF/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Brighthouse Finl analyst ratings.</strong></a></p>
<h2>About Brighthouse Finl</h2>
<p>Brighthouse Financial Inc is a United States-based provider of annuity products and life insurance through independent distribution channels and marketing arrangements with distribution partners. Its segments are Annuities, Life, and Run-off. It derives a majority of the revenue from the Annuities segment which includes variable, fixed, index-linked, and income annuities. The life segment includes variable, term, universal, and whole life policies.</p>
<h3>A Deep Dive into Brighthouse Finl's Financials</h3>
<p><strong>Market Capitalization Analysis:</strong> The company exhibits a lower market capitalization profile, positioning itself below industry averages. This suggests a smaller scale relative to peers.</p>
<p><strong>Revenue Growth:</strong> Brighthouse Finl's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>75.74%</strong>. This indicates a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Financials sector.</p>
<p><strong>Net Margin:</strong> Brighthouse Finl's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>7.64%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Brighthouse Finl's ROE surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>3.1%</strong> ROE, the company effectively utilizes shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> Brighthouse Finl's ROA lags behind industry averages, suggesting challenges in maximizing returns from its assets. With an ROA of <strong>0.06%,</strong> the company may face hurdles in achieving optimal financial performance.</p>
<p><strong>Debt Management:</strong> Brighthouse Finl's debt-to-equity ratio is below the industry average at <strong>0.57</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>Analyst Ratings: What Are They?</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Brighthouse Financial, Inc. - Common Stock

Brighthouse Finl Stock: A Deep Dive Into Analyst Perspectives (4 Ratings)

<p>In the preceding three months, 18 analysts have released ratings for Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">8</td>
<td align="right">8</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">4</td>
<td align="right">5</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $507.22, a high estimate of $600.00, and a low estimate of $465.00. This upward trend is apparent, with the current average reflecting a 0.92% increase from the previous average price target of $502.61.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734555647_0.png" alt="price target chart" /></p>
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
<p>An in-depth analysis of recent analyst actions unveils how financial experts perceive Microsoft. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$515.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Raises</td>
<td>Buy</td>
<td>$525.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Gregg Moskowitz</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$510.00</td>
<td>$480.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Karl Keirstead</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$500.00</td>
<td>$510.00</td>
</tr>
<tr>
<td>Mark Murphy</td>
<td>JP Morgan</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$465.00</td>
<td>$470.00</td>
</tr>
<tr>
<td>Derrick Wood</td>
<td>TD Cowen</td>
<td>Lowers</td>
<td>Buy</td>
<td>$475.00</td>
<td>$495.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$470.00</td>
<td>$470.00</td>
</tr>
<tr>
<td>Keith Weiss</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$548.00</td>
<td>$506.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$600.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Mark Moerdler</td>
<td>Bernstein</td>
<td>Lowers</td>
<td>Outperform</td>
<td>$500.00</td>
<td>$501.00</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Buy</td>
<td>$497.00</td>
<td>$500.00</td>
</tr>
<tr>
<td>Jackson Ader</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$505.00</td>
<td>$490.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Lowers</td>
<td>Overweight</td>
<td>$470.00</td>
<td>$485.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Lowers</td>
<td>Buy</td>
<td>$500.00</td>
<td>$515.00</td>
</tr>
<tr>
<td>Joel Fishbein</td>
<td>Truist Securities</td>
<td>Maintains</td>
<td>Buy</td>
<td>$600.00</td>
<td>$600.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$475.00</td>
<td>$475.00</td>
</tr>
<tr>
<td>Gil Luria</td>
<td>DA Davidson</td>
<td>Maintains</td>
<td>Neutral</td>
<td>$475.00</td>
<td>$475.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Microsoft. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of Microsoft compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Microsoft's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Microsoft's market standing. Stay informed and make well-considered decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MSFT/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Microsoft analyst ratings.</strong></a></p>
<h2>Delving into Microsoft's Background</h2>
<p>Microsoft develops and licenses consumer and enterprise software. It is known for its Windows operating systems and Office productivity suite. The company is organized into three equally sized broad segments: productivity and business processes (legacy Microsoft Office, cloud-based Office 365, Exchange, SharePoint, Skype, LinkedIn, Dynamics), intelligence cloud (infrastructure- and platform-as-a-service offerings Azure, Windows Server OS, SQL Server), and more personal computing (Windows Client, Xbox, Bing search, display advertising, and Surface laptops, tablets, and desktops).</p>
<h3>Microsoft's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.</p>
<p><strong>Revenue Growth:</strong> Over the 3 months period, Microsoft showcased positive performance, achieving a revenue growth rate of <strong>16.04%</strong> as of 30 September, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> Microsoft's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>37.61%,</strong> the company showcases strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Microsoft's ROE excels beyond industry benchmarks, reaching <strong>8.87%</strong>. This signifies robust financial management and efficient use of shareholder equity capital.</p>
<p><strong>Return on Assets (ROA):</strong> The company's ROA is a standout performer, exceeding industry averages. With an impressive ROA of <strong>4.77%,</strong> the company showcases effective utilization of assets.</p>
<p><strong>Debt Management:</strong> Microsoft's debt-to-equity ratio is below the industry average at <strong>0.21</strong>, reflecting a lower dependency on debt financing and a more conservative financial approach.</p>
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
<p>Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. </p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


MSFT

Microsoft Stock: A Deep Dive Into Analyst Perspectives (18 Ratings)

<p>29 analysts have expressed a variety of opinions on MongoDB (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MDB#NASDAQ">MDB</a>) over the past quarter, offering a diverse set of opinions from bullish to bearish.</p>
<p>In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">12</td>
<td align="right">13</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">10</td>
<td align="right">12</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">1</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>In the assessment of 12-month price targets, analysts unveil insights for MongoDB, presenting an average target of $379.66, a high estimate of $430.00, and a low estimate of $220.00. Witnessing a positive shift, the current average has risen by 10.35% from the previous average price target of $344.04.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734555630_0.png" alt="price target chart" /></p>
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
<p>The perception of MongoDB by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ivan Feinseth</td>
<td>Tigress Financial</td>
<td>Raises</td>
<td>Buy</td>
<td>$430.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Blair Abernethy</td>
<td>Rosenblatt</td>
<td>Announces</td>
<td>Buy</td>
<td>$350.00</td>
<td>-</td>
</tr>
<tr>
<td>Tyler Radke</td>
<td>Citigroup</td>
<td>Raises</td>
<td>Buy</td>
<td>$430.00</td>
<td>$400.00</td>
</tr>
<tr>
<td>Brian White</td>
<td>Monness, Crespi, Hardt</td>
<td>Announces</td>
<td>Sell</td>
<td>$220.00</td>
<td>-</td>
</tr>
<tr>
<td>Steve Koenig</td>
<td>Macquarie</td>
<td>Announces</td>
<td>Neutral</td>
<td>$300.00</td>
<td>-</td>
</tr>
<tr>
<td>David Hynes</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$385.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Patrick Walravens</td>
<td>JMP Securities</td>
<td>Maintains</td>
<td>Market Outperform</td>
<td>$380.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Andrew Nowinski</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$425.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Miller Jump</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$320.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$395.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$425.00</td>
<td>$360.00</td>
</tr>
<tr>
<td>Ittai Kidron</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$405.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Rishi Jaluria</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$400.00</td>
<td>$350.00</td>
</tr>
<tr>
<td>Kash Rangan</td>
<td>Goldman Sachs</td>
<td>Raises</td>
<td>Buy</td>
<td>$390.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Patrick Colville</td>
<td>Scotiabank</td>
<td>Raises</td>
<td>Sector Perform</td>
<td>$350.00</td>
<td>$295.00</td>
</tr>
<tr>
<td>William Power</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$390.00</td>
<td>$380.00</td>
</tr>
<tr>
<td>Matthew Broome</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Neutral</td>
<td>$320.00</td>
<td>$275.00</td>
</tr>
<tr>
<td>Sanjit Singh</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$350.00</td>
<td>$340.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$400.00</td>
<td>$375.00</td>
</tr>
<tr>
<td>Mike Cikos</td>
<td>Needham</td>
<td>Raises</td>
<td>Buy</td>
<td>$415.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$425.00</td>
<td>$425.00</td>
</tr>
<tr>
<td>Brad Reback</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$360.00</td>
<td>$325.00</td>
</tr>
<tr>
<td>Eric Heath</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$375.00</td>
<td>$330.00</td>
</tr>
<tr>
<td>William Power</td>
<td>Baird</td>
<td>Raises</td>
<td>Outperform</td>
<td>$380.00</td>
<td>$305.00</td>
</tr>
<tr>
<td>Yun Kim</td>
<td>Loop Capital</td>
<td>Raises</td>
<td>Buy</td>
<td>$400.00</td>
<td>$315.00</td>
</tr>
<tr>
<td>Brent Bracelin</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$425.00</td>
<td>$335.00</td>
</tr>
<tr>
<td>Raimo Lenschow</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$345.00</td>
<td>$290.00</td>
</tr>
<tr>
<td>Rudy Kessinger</td>
<td>DA Davidson</td>
<td>Raises</td>
<td>Buy</td>
<td>$340.00</td>
<td>$330.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to MongoDB. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of MongoDB compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of MongoDB's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of MongoDB's market position. Stay informed and make well-informed decisions with our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/MDB/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on MongoDB analyst ratings.</strong></a></p>
<h2>Get to Know MongoDB Better</h2>
<p>Founded in 2007, MongoDB is a document-oriented database. MongoDB provides both licenses as well as subscriptions as a service for its NoSQL database. MongoDB's database is compatible with all major programming languages and is capable of being deployed for a variety of use cases.</p>
<h3>Financial Insights: MongoDB</h3>
<p><strong>Market Capitalization Analysis:</strong> Above industry benchmarks, the company's market capitalization emphasizes a noteworthy size, indicative of a strong market presence.</p>
<p><strong>Revenue Growth:</strong> MongoDB's revenue growth over a period of 3 months has been noteworthy. As of 31 October, 2024, the company achieved a revenue growth rate of approximately <strong>22.27%</strong>. This indicates a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Information Technology sector.</p>
<p><strong>Net Margin:</strong> MongoDB's net margin is impressive, surpassing industry averages. With a net margin of <strong>-1.85%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> MongoDB's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>-0.68%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> MongoDB's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive <strong>-0.31%</strong> ROA, the company effectively utilizes its assets for optimal returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.77</strong>, MongoDB adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.</p>
<p>In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


Where MongoDB Stands With Analysts

<p>In the preceding three months, 16 analysts have released ratings for Globus Medical (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GMED#NYSE">GMED</a>), presenting a wide array of perspectives from bullish to bearish.</p>
<p>The table below provides a snapshot of their recent ratings, showcasing how sentiments have evolved over the past 30 days and comparing them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">7</td>
<td align="right">6</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">3</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $91.31, a high estimate of $115.00, and a low estimate of $78.00. Surpassing the previous average price target of $81.81, the current average has increased by 11.61%.</p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734555621_0.png" alt="price target chart" /></p>
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
<p>The analysis of recent analyst actions sheds light on the perception of Globus Medical by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Richard Newitter</td>
<td>Truist Securities</td>
<td>Raises</td>
<td>Hold</td>
<td>$90.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Jason Wittes</td>
<td>Roth MKM</td>
<td>Raises</td>
<td>Buy</td>
<td>$115.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$91.00</td>
<td>$87.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$95.00</td>
<td>$88.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$85.00</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$83.00</td>
</tr>
<tr>
<td>Drew Ranieri</td>
<td>Morgan Stanley</td>
<td>Raises</td>
<td>Equal-Weight</td>
<td>$83.00</td>
<td>$74.00</td>
</tr>
<tr>
<td>Mathew Blackman</td>
<td>Stifel</td>
<td>Raises</td>
<td>Buy</td>
<td>$92.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>William Plovanic</td>
<td>Canaccord Genuity</td>
<td>Raises</td>
<td>Buy</td>
<td>$85.00</td>
<td>$79.00</td>
</tr>
<tr>
<td>Jason Wittes</td>
<td>Roth MKM</td>
<td>Maintains</td>
<td>Buy</td>
<td>$100.00</td>
<td>$100.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$92.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Vik Chopra</td>
<td>Wells Fargo</td>
<td>Raises</td>
<td>Overweight</td>
<td>$88.00</td>
<td>$78.00</td>
</tr>
<tr>
<td>Matt O'Brien</td>
<td>Piper Sandler</td>
<td>Raises</td>
<td>Overweight</td>
<td>$100.00</td>
<td>$80.00</td>
</tr>
<tr>
<td>Craig Bijou</td>
<td>B of A Securities</td>
<td>Raises</td>
<td>Underperform</td>
<td>$80.00</td>
<td>$55.00</td>
</tr>
<tr>
<td>Ryan Zimmerman</td>
<td>BTIG</td>
<td>Raises</td>
<td>Buy</td>
<td>$78.00</td>
<td>$77.00</td>
</tr>
<tr>
<td>Shagun Singh</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$80.00</td>
<td>$78.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Globus Medical. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Globus Medical compared to the broader market.</li>
<li><strong>Price Targets:</strong> Gaining insights, analysts provide estimates for the future value of Globus Medical's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<p>For valuable insights into Globus Medical's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/GMED/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Globus Medical analyst ratings.</strong></a></p>
<h2>Discovering Globus Medical: A Closer Look</h2>
<p>Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions to hospitals, physicians, and surgical centers. The firm's products are organized into two categories: musculoskeletal solutions, which include medical devices and instruments used mostly for spinal and orthopedic procedures, and enabling technologies, which include advanced computer systems developed for enhancing surgical capabilities. The vast majority of the company's revenue is generated from musculoskeletal solutions products, and more than half of the revenue is earned in the United States.</p>
<h3>Globus Medical's Economic Impact: An Analysis</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Revenue Growth:</strong> Globus Medical's revenue growth over a period of 3 months has been noteworthy. As of 30 September, 2024, the company achieved a revenue growth rate of approximately <strong>63.1%</strong>. This indicates a substantial increase in the company's top-line earnings. When compared to others in the Health Care sector, the company excelled with a growth rate higher than the average among peers.</p>
<p><strong>Net Margin:</strong> Globus Medical's net margin falls below industry averages, indicating challenges in achieving strong profitability. With a net margin of <strong>8.28%,</strong> the company may face hurdles in effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Globus Medical's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of <strong>1.29%,</strong> the company may encounter challenges in delivering satisfactory returns for shareholders.</p>
<p><strong>Return on Assets (ROA):</strong> Globus Medical's ROA is below industry averages, indicating potential challenges in efficiently utilizing assets. With an ROA of <strong>1.03%,</strong> the company may face hurdles in achieving optimal financial returns.</p>
<p><strong>Debt Management:</strong> With a below-average debt-to-equity ratio of <strong>0.13</strong>, Globus Medical adopts a prudent financial strategy, indicating a balanced approach to debt management.</p>
<h2>The Significance of Analyst Ratings Explained</h2>
<p>Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.</p>
<p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights"><strong>Click here to stay ahead of the market</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


GMED

16 Analysts Have This To Say About Globus Medical

<p>Ratings for Axalta Coating Sys (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AXTA#NYSE">AXTA</a>) were provided by 7 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.</p>
<p>Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">6</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>Analysts have recently evaluated Axalta Coating Sys and provided 12-month price targets. The average target is $44.86, accompanied by a high estimate of $48.00 and a low estimate of $41.00. This current average reflects an increase of 2.35% from the previous average price target of $43.83. </p>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734555610_0.png" alt="price target chart" /></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<p>The perception of Axalta Coating Sys by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patrick Cunningham</td>
<td>Citigroup</td>
<td>Lowers</td>
<td>Neutral</td>
<td>$41.00</td>
<td>$45.00</td>
</tr>
<tr>
<td>John McNulty</td>
<td>BMO Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$48.00</td>
<td>$46.00</td>
</tr>
<tr>
<td>Eric Boyes</td>
<td>Evercore ISI Group</td>
<td>Announces</td>
<td>Outperform</td>
<td>$47.00</td>
<td>-</td>
</tr>
<tr>
<td>Arun Viswanathan</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$46.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>Michael Leithead</td>
<td>Barclays</td>
<td>Raises</td>
<td>Overweight</td>
<td>$44.00</td>
<td>$42.00</td>
</tr>
<tr>
<td>Aleksey Yefremov</td>
<td>Keybanc</td>
<td>Raises</td>
<td>Overweight</td>
<td>$45.00</td>
<td>$44.00</td>
</tr>
<tr>
<td>John Roberts</td>
<td>Mizuho</td>
<td>Raises</td>
<td>Outperform</td>
<td>$43.00</td>
<td>$42.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li><strong>Action Taken:</strong> In response to dynamic market conditions and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their reaction to recent developments related to Axalta Coating Sys. This insight gives a snapshot of analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Axalta Coating Sys compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts predict movements in price targets, offering estimates for Axalta Coating Sys's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.</li>
</ul>
<p>To gain a panoramic view of Axalta Coating Sys's market performance, explore these analyst evaluations alongside essential financial indicators. Stay informed and make judicious decisions using our Ratings Table.</p>
<p><a href="https://www.benzinga.com/quote/AXTA/analyst-ratings?utm_source=Benzinga Insights"><strong>Stay up to date on Axalta Coating Sys analyst ratings.</strong></a></p>
<h2>Get to Know Axalta Coating Sys Better</h2>
<p>Axalta Coating Systems Ltd is a manufacturer, marketer and distributor of high-performance coatings systems. It operates in two segments, The Performance Coatings segment provides liquid and powder coatings solutions to a fragmented and local customer base. Its end markets include refinish and industrial. The Mobility Coatings segment relates to the provision of coating technologies to original equipment manufacturers of light and commercial vehicles. The company operates in the geographic areas of North America, EMEA countries, Asia-Pacific and Latin America.</p>
<h3>Axalta Coating Sys's Financial Performance</h3>
<p><strong>Market Capitalization Analysis:</strong> Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.</p>
<p><strong>Positive Revenue Trend:</strong> Examining Axalta Coating Sys's financials over 3 months reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>0.84%</strong> as of 30 September, 2024, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Materials sector.</p>
<p><strong>Net Margin:</strong> Axalta Coating Sys's net margin is impressive, surpassing industry averages. With a net margin of <strong>7.65%,</strong> the company demonstrates strong profitability and effective cost management.</p>
<p><strong>Return on Equity (ROE):</strong> Axalta Coating Sys's ROE stands out, surpassing industry averages. With an impressive ROE of <strong>5.49%</strong>, the company demonstrates effective use of equity capital and strong financial performance.</p>
<p><strong>Return on Assets (ROA):</strong> Axalta Coating Sys's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of <strong>1.36%,</strong> the company showcases efficient use of assets and strong financial health.</p>
<p><strong>Debt Management:</strong> Axalta Coating Sys's debt-to-equity ratio stands notably higher than the industry average, reaching <strong>1.85</strong>. This indicates a heavier reliance on borrowed funds, raising concerns about financial leverage.</p>
<h2>Analyst Ratings: Simplified</h2>
<p>Analyst ratings serve as essential indicators of stock performance, provided by experts in banking and financial systems. These specialists diligently analyze company financial statements, participate in conference calls, and engage with insiders to generate quarterly ratings for individual stocks.</p>
<p>Some analysts will also offer forecasts for metrics like growth estimates, earnings, and revenue to provide further guidance on stocks. Investors who use analyst ratings should note that this specialized advice comes from humans and may be subject to error.</p>
<p><strong>Breaking: Wall Street's Next Big Mover</strong></p>
<p>Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;utm_source=benzinga-insights"><strong>Click here for urgent details</strong></a>.</p>
<p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>


AXTA

What 7 Analyst Ratings Have To Say About Axalta Coating Sys

WIIM

ABNB

AYRO

CAKE

CAVA

COOK

CTHR

DKNG

DUOL

FEBO

HTHT

IRBT

PHIN

PTON

SERV

TCOM

TSCO

Shares of companies within the broader consumer discretionary sector are trading lower amid overall market weakness following the Fed's rate decision to cut rates by 25 basis points.

<p>In a year marked by three consecutive rate cuts totaling 100 basis points, Federal Reserve Chair <strong>Jerome Powell </strong>said the Fed is shifting gears to a more cautious stance heading into 2025 as interest rates move tantalizingly close to a neutral <a href="https://www.benzinga.com/news/econ-s/24/12/42561549/fed-slashes-interest-rates-by-0-25-as-predicted-december-dot-plot-flags-only-2-potential-cuts-in-2025">environment for the economy.</a></p>
<p>Following the latest 25-basis-point reduction announced Wednesday, the federal funds rate now sits at 4.25%-4.5%, the lowest since January 2023.</p>
<p>&#8220;We&#8217;re significantly closer to neutral,&#8221; Powell said during the post-meeting press conference. &#8220;From this point forward, it's appropriate to move cautiously and look for further progress on inflation,&#8221; he added. </p>
<h3 class="wp-block-heading">Powell Confirms Slower Rate Cuts On The Horizon</h3>
<p>&#8220;I think from here it&#8217;s a new phase and we&#8217;re going to be cautious about further cuts," the Fed chair said.</p>
<p>The Fed&#8217;s December dot plot projects only two additional 25-basis-point cuts in 2025, compared to the four anticipated in September. The updated projections peg the federal funds rate at 3.9% by the end of next year and 3.4% by the close of 2026.</p>
<p>&#8220;With today&#8217;s action, we have lowered our policy rate by a full percentage point from its peak, and our policy stance is now significantly less restrictive,&#8221; Powell said. </p>
<p>This shift toward caution was reflected in the FOMC's statement, which introduced new language about the &#8220;extent and timing&#8221; of future adjustments. </p>
<p>Powell indicated that &#8220;extent&#8221; refers to how much room the Fed has left to cut rates without overstimulating the economy, while &#8220;timing&#8221; suggests a slower pace of change going forward.</p>
<h3 class="wp-block-heading">Inflation Job Not Over, Labor Market Gradually Softer</h3>
<p>Despite this year's progress, inflation remains a thorn in the Fed's side. </p>
<p>Headline PCE inflation is now expected to reach 2.5% in 2025, up from the September estimate of 2.1%. Core PCE inflation is also forecast to hit 2.5%, up from 2.2% previously. </p>
<p>Powell highlighted the challenges of achieving the Fed's 2% target: "While we've made a great deal of progress, it has been slower than we had hoped."</p>
<p>Despite the challenges, Powell struck a confident tone about the Fed's ability to bring inflation sustainably back to its 2% target. </p>
<p>"We're not going to settle for anything less than 2%," Powell said. "It might take another year or two, but we are on the path."</p>
<p>Powell described conditions as &#8220;solid,&#8221; with the unemployment rate at 4.2%, the same as it was in July.</p>
<p>While job creation has slowed, Powell dismissed concerns of significant downside risks. "The labor market is gradually cooling in an orderly way," he said.</p>
<p>The hiring rate remains low, signaling reduced demand for workers, but layoffs are not increasing, Powell said. "This is a good labor market," he added. &#8220;Wages are growing at a healthy, sustainable pace, and we aim to keep it that way.&#8221;</p>
<h3 class="wp-block-heading">Trump And Tariffs Risks</h3>
<p>Powell also addressed questions on fiscal policy risks under the incoming Trump administration and inflationary effects of tariffs.</p>
<p>When asked whether policymakers factored in risks tied to the potential policy shifts under a new Trump administration, Powell struck a measured tone, stating the Fed is monitoring potential fiscal developments but refraining from speculation until specific policies are announced. </p>
<p>"We're in a good place, but fiscal changes can influence inflation and economic growth," he said.</p>
<p>&#8220;We're in the phase of monitoring potential outcomes, not making policy assumptions.&#8221;</p>
<p>On tariffs, Powell said that while one-time tariff-driven price increases don't always translate into persistent inflation, the Fed will take a &#8220;careful and measured approach&#8221; in evaluating the effects if new tariffs are enacted. </p>
<h3 class="wp-block-heading">Market Plummets After Powell&#8217;s Remarks</h3>
<p>Following Powell&#8217;s remarks, Fed futures imply just 37 basis points of cuts in 2025, down from 49 basis points immediately after the Fed statement. </p>
<p>The S&amp;P 500 index — as tracked by the <strong>SPDR S&amp;P 500 ETF Trust</strong> (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>) — extended its session losses during Powell&#8217;s press conference, tumbling by 2.6%, eyeing its worst session since September 2022.</p>
<p>The Nasdaq 100 tumbled by 3.5%, the Dow fell 2.3% and small cap stocks in the Russell 2000 tanked over 4%. </p>
<p>The U.S. dollar index, trackd by the <strong>Invesco DB USD Index Bullish Fund ETF </strong>(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/UUP#NYSE">UUP</a>), rocketed by 1.2%, reaching highs last seen in November 2022.</p>
<p>Gold plummeted over 2% and silver fell by 3.5%.</p>
<p><strong>Bitcoin</strong> nosedived by 5.5%, hovering around $100,000.</p>
<p><figure class="wp-block-embed is-type-video is-provider-youtube wp-block-embed-youtube wp-embed-aspect-16-9 wp-has-aspect-ratio"><br />
<div class="wp-block-embed__wrapper">
<iframe loading="lazy" title="&#x1f534;WATCH LIVE: US Fed Rate Cut &#x7C; FOMC Meeting &#x7C; Jerome Powell Speech LIVE &#x7C; December 18th, 2024" width="500" height="281" src="https://www.youtube.com/embed/WQdK2IixF5c?feature=oembed" frameborder="0" allow="accelerometer; autoplay; clipboard-write; encrypted-media; gyroscope; picture-in-picture; web-share" referrerpolicy="strict-origin-when-cross-origin" allowfullscreen></iframe>
</div>
<p></p></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/economics/macro-economic-events/24/12/42558766/mortgage-applications-dip-as-rates-climb-it-is-still-cheaper-to-rent-than-purchase-for-82-out-of-97-major-cities">Mortgage Applications Dip As Rates Climb: &#8216;It Is Still Cheaper To Rent Than Purchase For 82 Out Of 97 Major Cities&#8217;</a></strong></li>
</ul>
<p><em>Federal Reserve Chair Jerome Powell speaks at Dec. 18, 2024 press conference following interest rate cut. Photo courtesy of the Federal Reserve.</em></p>


Equities

Broad U.S. Equity ETFs

Econ #s

Economics

Federal Reserve

ETFs

PowerShares DB US Dollar Index Bullish Fund

Fed's Powell Shocks Markets After Interest Rate Cut: 'It's A New Phase'

BLDR

IESC

Shares of homebuilders, construction and household durables stocks are trading lower amid overall market weakness following the Fed's rate decision to cut rates by 25 basis points.

ASAI

CASK

CASY

CELH

HNST

ORIS

SENEB

SKIN

WALD

Shares of companies within the broader consumer staples sector are trading lower amid overall market weakness following the Fed's rate decision to cut rates by 25 basis points.

<p>ASML Holding (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASML#NASDAQ">ASML</a>) has outperformed the market over the past 10 years by 9.75% on an annualized basis producing an average annual return of 20.73%. Currently, ASML Holding has a market capitalization of $282.30 billion. </p>
<p><strong>Buying $100 In ASML:</strong> If an investor had bought $100 of ASML stock 10 years ago, it would be worth <strong>$655.17</strong> today based on a price of $717.54 for ASML at the time of writing.</p>
<h3>ASML Holding's Performance Over Last 10 Years</h3>
<p><img src="https://www.benzinga.com/files/images/story/2024/1734555312_0.png" alt="comp_fig" /></p>
<p>Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.</p>
<p><em>This article was generated by Benzinga's automated content engine and reviewed by an editor.</em></p>


ASML

Here's How Much You Would Have Made Owning ASML Holding Stock In The Last 10 Years

MESA

SRFM

Shares of airline companies are trading lower amid overall market weakness following the Fed's rate decision to cut rates by 25 basis points.

GOLD

MTRN

PAAS

RGLD

SBSW

SCCO

TECK

Shares of stocks in the broader metals and mining sector are trading lower amid overall market weakness following the Fed's rate decision to cut rates by 25 basis points.

GTLS

LECO

NDSN

PCAR

PPIH

Shares of machine companies are trading lower amid overall market weakness following the Fed's rate decision to cut rates by 25 basis points.

<p><strong>SEALSQ Corp&#8217;s</strong> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LAES#NASDAQ">LAES</a>) are trading lower Wednesday following the company's announcement of a registered direct offering priced well below recent trading levels. Here&#8217;s <a href="https://www.benzinga.com/quote/LAES/news">what you need to know.</a></p>
<p><strong>What To Know</strong>: The company revealed a securities purchase agreement with institutional investors to sell 13,157,896 ordinary shares at a public offering price of $1.90 per unit. The offering is expected to generate gross proceeds of $25 million before deducting commissions and expenses. Investors have reacted negatively to the pricing, which represents a steep discount and raises concerns about potential dilution.</p>
<p>SEALSQ plans to use the funds to advance the deployment of its post-quantum semiconductor technology and ASIC capabilities in the United States, as well as to support working capital and general corporate purposes. The offering, managed by Maxim Group LLC as the sole placement agent, is scheduled to close on or around Dec. 19 2024, pending customary closing conditions.</p>
<p>This move comes under a previously approved shelf registration statement filed with the U.S. Securities and Exchange Commission in late November. </p>
<p>SEALSQ focuses on post-quantum cryptography and semiconductor solutions, which aim to address emerging threats posed by advancements in quantum computing. However, the immediate reaction to the offering potentially highlights investor unease over the financial terms and their impact on shareholder value.</p>
<p><strong>LAES Price Action: </strong>SEALSQ shares were down 21.5% at $2.33 at the time of writing, according to <a href="https://pro.benzinga.com/dashboard">Benzinga Pro.</a></p>
<p><figure class="wp-block-image size-large is-resized"><a href="https://benzinga.slack.com/archives/D072651PB4K/p1733167806337199"><img loading="lazy" decoding="async" width="1024" height="536" src="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18152742/LAES-2-1024x536.png" alt="" class="wp-image-698503" style="width:575px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18152742/LAES-2-1024x536.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18152742/LAES-2-300x157.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18152742/LAES-2-768x402.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2024/12/18152742/LAES-2.png 1470w" sizes="(max-width: 1024px) 100vw, 1024px" /></a></figure></p>
<p><strong>Read Next:</strong></p>
<ul>
<li><strong><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/12/42562515/nike-q2-earnings-preview-analyst-says-athletic-brand-early-in-turnaround-journey-with-new-ceo">Nike Q2 Earnings Preview: Analyst Says Athletic Brand Early In &#8216;Turnaround Journey&#8217; With New CEO</a></strong></li>
</ul>
<p><em>Image Via Shutterstock.</em></p>


LAES

SEALSQ Shares Are Down Today: What's Going On?

AESI

AMTX

AROC

BROG

CRGY

CSAN

EQNR

EZFL

GPRE

MIND

NEHC

TRGP

VIST

Shares of oil and gas companies are trading lower amid overall market weakness following the Fed's rate decision to cut rates by 25 basis points.

Cipher Pharmaceuticals (TSE:CPH) has released an update. Cipher Pharmaceuticals Inc. has recently strengthened its executive team by appointing Ham...

Cipher Pharmaceuticals Welcomes New Chief Business Officer

In a report released today, Justin Keywood from Stifel Nicolaus maintained a Buy rating on Cipher Pharmaceuticals (CPHRF – Research Report), with a...

Cipher Pharmaceuticals (CPHRF) Receives a Buy from Stifel Nicolaus

Stifel Nicolaus Sticks to Their Buy Rating for Cipher Pharmaceuticals (CPHRF)

Stifel raised the firm's price target on Cipher Pharmaceuticals (CPHRF) to C$19 from C$17 and keeps a Buy rating on the shares. Published first on ...

Cipher Pharmaceuticals price target raised to C$19 from C$17 at Stifel

Cipher Pharmaceuticals (TSE:CPH) has released an update. Cipher Pharmaceuticals is set to release its Q3 2024 financial results on November 7, 2024...

Cipher Pharmaceuticals Announces Q3 2024 Financial Results

Cipher Pharmaceuticals (TSE:CPH) has released an update. Cipher Pharmaceuticals reported significant growth in the third quarter of 2024, with tota...

Cipher Pharmaceuticals' Revenue Soars After Natroba Acquisition

Cipher Pharmaceuticals Inc ( ($CPHRF) ) has released its Q3 earnings. Here is a breakdown of the information Cipher Pharmaceuticals Inc presented t...

Cipher Pharmaceuticals Q3 2024 Results: Growth and Acquisitions

Stifel lowered the firm's price target on Cipher Pharmaceuticals (CPHRF) to C$17 from C$19 and keeps a Buy rating on the shares. Published first on...

Cipher Pharmaceuticals price target lowered to C$17 from C$19 at Stifel

Donville Kent Asset Management November 2024 Commentary

Cipher Pharmaceuticals (TSE:CPH) has released an update. Cipher Pharmaceuticals announced that their partner, Moberg Pharma, reported disappointing...

Cipher Pharmaceuticals Faces Setback but Eyes Growth

CNSWF

CRFQF

EHMEF

ETOLF

KSIOF

MDALF

PRLPF

VFORF

VHIBF

Small Cap

Press Releases

Cipher Pharmaceuticals Reports First Quarter 2024 Results

Cipher Pharmaceuticals Announces Results of Annual and Special Meeting of Shareholders

Comments

(CPHRF) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga